Published 4 days ago • loading... • Updated 4 days ago

Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million

On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. Released its 2024 annual results, reporting from Hangzhou, China, on March 28, 2025.
This announcement highlights the company's commitment to its mission, "Innovation for Quality Life," and its focus on advancing medical technology.
In 2024, Zylox-Tonbridge achieved its first full-year of profitability, reporting revenue of USD 109.4 million, a 48.3% increase year-on-year, and a net profit exceeding USD 14 million, driven by economies of scale and strategic participation in centralized procurement.
Zylox-Tonbridge actively participated in centralized procurement, securing multiple successful bids with its robust product portfolio, including the SilverSnake Intracranial Support Catheter and the ZYLOX Penguin Peripheral Venous Stent System, demonstrating a focus on vascular intervention products.
Zylox-Tonbridge is expanding its global presence, with 20 products commercialized in 24 countries and regions, including Germany, Italy, Argentina, Brazil, and the UAE, resulting in overseas revenue of USD 3.2 million in 2024 and a four-year compound annual growth rate of 87%.

Insights by Ground AI

Does this summary seem wrong?

47 Articles

All

Left

Center

Right

The Berkshire Eagle

+44 Reposted by 44 other sources

Center

Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million

HANGZHOU, China, March 28, 2025 /PRNewswire/ -- On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its 2024 annual results. In 2024, the Company reported revenue of USD 109.4…

4 days ago

Read Full Article

pressreach.com

Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million - PressReach

HANGZHOU, China, March 28, 2025 /PRNewswire/ — On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as “Zylox-Tonbridge” or the “Company”) released its 2024 annual results. In 2024, the Company reported revenue of USD 109.4 million, a year-on-year increase of 48.3%, and achieved a net profit exceeding USD 14 million, marking its first full-year profitability. Amid a dynamic market environment, Z…

4 days ago

Read Full Article

dirhongkong.com

Hua Medicine Announces 2024 Annual Results – DIR HONGKONG

– HuaTangNing completed its first full year for reimbursement under the National Reimbursement Drug List (NRDL), with continued expansion in hospital coverage. Compared with the 2023 year, sales volume increased by approximately 740%. – Sales revenue increased by 234% compared with the 2023 year, with cash reserves exceeding RMB 1 billion to fully support future R&D and commercialization activities. – A Phase I clinical study of our second-gener…

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year